Pharmacyclics (PCYC +5.5%) says that follow-up findings from an ongoing Phase II study suggest that its investigational oral agent ibrutinib resulted in "high and durable responses" and was generally well toleratedin patients with relapsed or refractory mantle cell lymphoma.
Pharmacyclics (PCYC +5.5%) says that follow-up findings from an ongoing Phase II study suggest...
From other sites
at CNBC.com (Jan 13, 2015)
at CNBC.com (Dec 5, 2014)
at CNBC.com (Sep 17, 2014)
at CNBC.com (Jul 29, 2014)
at CNBC.com (Jul 23, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs